期刊文献+

利奈唑胺对老年患者血液系统的影响 被引量:4

The effects on hematological system among elderly patient caused by linezolid
下载PDF
导出
摘要 目的探讨利奈唑胺对老年患者血液系统产生的不良影响,为合理用药和提高老年患者用药安全性提供参考。方法回顾性分析2011~2012年在住院期间曾使用利奈唑胺抗感染治疗的老年患者血液系统异常的发生率及特点。结果使用利奈唑胺后15.6%患者白细胞降低至正常值以下,但停药后多数可恢复。42.2%患者发生血红蛋白下降,其中不到半数患者停药后可恢复至治疗前水平,且需时间较长。78.1%患者出现血小板降低,其中42.2%降低至正常值以下,25%降至50×10^9/L以下,大多数患者停药2周后血小板可恢复至治疗前水平。结论老年患者使用利奈唑胺后血液系统不良反应的发生率和严重程度高于其他人群,故老年患者使用利奈唑胺过程中需密切监测血常规。 Objective To investigate the adverse effects on hematological system among elderly patient caused by linezolid. Methods The clinical data of 64 elderly patients who were treated with linezolid between 2011 ~ 2012 when hospitalized in our department were analyzed retrospectively. Results Leukocytopenia occurred in 15. 6 percent of patients,but normalized soon after drug withdrawal in most of them. Decrease of hemoglobin occurred in 42. 2 percent of patients,and less than half of them could return to the baseline. The incidence of thrombocytopenia was42. 2%,and the platelet count of 16( 25%) patients decreased below 50 × 10^9/L. But the platelet count of most patients would return to the baseline at two weeks after drug withdrawal. Conclusion The incidence and the severity of adverse reactions to hematological system caused by linezolid in elderly patient were higher than that in general population. Complete blood count should be monitored carefully in elderly patients who are treated with linezolid.
出处 《临床和实验医学杂志》 2014年第17期1457-1460,共4页 Journal of Clinical and Experimental Medicine
关键词 老年人 利奈唑胺 血液系统 不良反应 Elderly Linezolid Hematological system Adverse reactions
  • 相关文献

参考文献5

二级参考文献92

  • 1林东昉,吴菊芳,张婴元,郑经川,缪竞智,郑丽叶,盛瑞媛,周新,沈华浩,吴卫红,周乐,汪复.利奈唑胺与万古霉素治疗革兰阳性菌感染的随机、双盲、对照、多中心临床试验[J].中国感染与化疗杂志,2009,9(1):10-17. 被引量:56
  • 2王从容.抗菌新药——利奈唑胺[J].中国医院药学杂志,2006,26(5):614-616. 被引量:23
  • 3陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 4Aneziokoro CO, Cannon JP, Pachucki CT, et al. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis [J]. J Chemother, 2005, 17 (6) : 643-650.
  • 5Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program [J]. Clin Infect Dis, 2003, 36(2) : 159-68.
  • 6Attassi K, Hershberger E, Alam R, et al. Thromboeytopenia associated with linezolid therapy[J]. Clin Infect Dis, 2002, 34(5 ) : 695 -698.
  • 7Matsumoto K, Takeshita A, lkawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunctinn[J], Int J Antimierob Agents. 2010, 36(2) : 179-181.
  • 8黎颖然,卢荣枝.利余唑胺相关新生儿血小板减少4例[J].药物不良反府杂志,2011,13(4):243-244.
  • 9Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability [J]. Biopharm Drug Dispos, 2001, 22(3) : 91-97.
  • 10Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia [J]. Stand J Infect Dis, 2012, 44(1) : 60-64.

共引文献81

同被引文献40

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部